ProQR Therapeutics N.V. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by de Boer Daniel Anton, was filed 03 Aug 2026.
ProQR Therapeutics N.V.: what insiders have been doing
ProQR Therapeutics N.V. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 8 November 2026, 5 filings were filed, from 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 5 purchases totalling €1.2M, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive and 1 chief executive. The largest single trade was a purchase of €307k by de Boer Daniel Anton, published on 3 August 2026, equal to 0.14% of the market capitalisation.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 3 August 2026, which is 97 days ago. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,813 companies, median 19 filings), a count of 5 filings is below the norm. Looking back to 2026, when coverage begins, insiders filed 5 purchases and no sales. On the fundamentals side, the SEC filing (20-F) for the period ending 31 December 2025 lists net income at -42.2 m EUR.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +14.2%Entry US$1.83 · Close at T+30 US$2.09
- +29.3%Entry US$1.81 · Close at T+30 US$2.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate ProQR Therapeutics N.V. Strong Buy (bullish), based on 9 analysts. Average price target: US$7.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 200,000 shares@ US$1.76980.14% mcap41.3% of flowOrdinary SharesSEC:0001104659-26-089780:0Canonical exit: 29 Oct 2026 (T+90)
- 150,000 shares@ US$1.71950.11% mcap100.0% of flowOrdinary SharesSEC:0001104659-26-085234:0Canonical exit: 15 Oct 2026 (T+90)
- 150,000 shares@ US$1.740.11% mcap30.7% of flowOrdinary SharesSEC:0001104659-26-082890:0Canonical exit: 7 Oct 2026 (T+90)
- 150,000 shares@ US$1.590.098% mcap28.0% of flowOrdinary SharesSEC:0001104659-26-081762:0Canonical exit: 5 Oct 2026 (T+90)
- 150,000 sharesOrdinary SharesSEC:0001104659-26-079316:0Canonical exit: 24 Sept 2026 (T+90)
5 of 5 declarations
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing treatments for genetic diseases. It specializes in RNA-based therapies to address hereditary disorders.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
